Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Inhibition of food intake in obese subjects by peptide YY3-36.

• R L Batterham, Mark A. Cohen, +5 authors Stephen R. Bloom
• The New England journal of medicine
• 2003

BACKGROUND The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food… (More)

Ghrelin enhances appetite and increases food intake in humans.

• Alison M. Wren, Leighton J. Seal, +6 authors Stephen R. Bloom
• The Journal of clinical endocrinology and…
• 2001

Ghrelin is a recently identified endogenous ligand for the growth hormone secretagogue receptor. It is synthesized predominantly in the stomach and found in the circulation of healthy humans. Ghrelin… (More)

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

• Christina M. Edwards, Sarah A Stanley, +5 authors Steven R. Bloom
• American journal of physiology. Endocrinology and…
• 2001

Exendin-4 is a long-acting potent agonist of the glucagon-like peptide 1 (GLP-1) receptor and may be useful in the treatment of type 2 diabetes and obesity. We examined the effects of an intravenous… (More)

Inflammatory disease processes and interactions with nutrition.

• Philip C Calder, Rene Albers, +18 authors Jun-jun Zhao
• The British journal of nutrition
• 2009

Inflammation is a stereotypical physiological response to infections and tissue injury; it initiates pathogen killing as well as tissue repair processes and helps to restore homeostasis at infected… (More)

Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial.

• Nicola Marguerite Neary, Caroline J. Small, +7 authors Stephen R. Bloom
• The Journal of clinical endocrinology and…
• 2004

There is a pressing need for more effective appetite-stimulatory therapies for many patient groups including those with cancer. We have previously demonstrated that the gastric hormone ghrelin… (More)

Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial1234

• Susan A Jebb, Julie A Lovegrove, +6 authors Thomas A. B. Sanders
• The American journal of clinical nutrition
• 2010

BACKGROUND Insulin sensitivity (Si) is improved by weight loss and exercise, but the effects of the replacement of saturated fatty acids (SFAs) with monounsaturated fatty acids (MUFAs) or… (More)

Pancreatic polypeptide reduces appetite and food intake in humans.

• R L Batterham, Carel W le Roux, +6 authors Stephen R. Bloom
• The Journal of clinical endocrinology and…
• 2003

Pancreatic polypeptide (PP) is a gut hormone released from the pancreas in response to ingestion of food. Plasma PP has been shown to be reduced in conditions associated with increased food intake… (More)

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

• Tricia M.M Tan, Benjamin C. T. Field, +11 authors Stephen R. Bloom
• Diabetes
• 2013

Glucagon and glucagon-like peptide (GLP)-1 are the primary products of proglucagon processing from the pancreas and gut, respectively. Giving dual agonists with glucagon and GLP-1 activity to… (More)

A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men.

• Audrey E. Brynes, C Mark Edwards, +4 authors Gary S. Frost
• The British journal of nutrition
• 2003

Postprandial concentrations of glucose, insulin and triacylglycerols (TG) correlate to risk for CHD. Carbohydrates affect many metabolites that could have a potential effect on cardiovascular risk… (More)

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

• Katie Wynne, Adrian J Park, +4 authors Stephen R. Bloom
• International Journal of Obesity
• 2006

Background:Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.Objective:To determine whether oxyntomodulin alters energy… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›